LoginMy Member Benefitsarchivesresearchyour teamabout usFAQLog out
×
Share
Access Your Profit Alerts
Profit Alerts

Biotech & Pharma Alerts

Follow topic
Biotech & Pharma Alerts

Get biotech and pharma industry news delivered straight to your inbox the moment it's released.

Biotechnology

How to Cash In on the Biggest Medical Breakthrough of the Decade

by Leave a Comment

Imagine if all it took to treat a case of cancer was taking out the trash.

Now, I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here's the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as "degraders."

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body's own molecular trash disposal systems.

This is one of the most exciting breakthroughs I've come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I'm going to reveal a way investors can target the entire class of protein degraders with one savvy move...

Technology

You Can Double Your Money Fighting the $1.1 Trillion Disease Killing America

by Leave a Comment

I recently got the kind of news that no child wants to hear about an aging parent.

Here's the thing: I count my blessings that my dad lived so long. After all, he's a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.

Honestly, he's lucky he lived as long as he did. But that still doesn't make the aging process any easier, at least not on the body.

He recently had a second knee replacement that didn't go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can't drive right now.

At 86, he recently learned he has congestive heart failure. That's a condition in which the heart doesn't pump as strongly as it should, leading to a buildup of fluids.

As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.

And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients – and show you five reasons why it's set to double in as little as three-and-a-half years…

Read more here...

Technology

The Answer to Big Pharma's Biggest Problem Could Double Your Money in Just Three Years

by Leave a Comment

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.

With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.

It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.

And it's been doubling its earnings, on average, every 18 months...

stocks

This Small-Cap Pharma Stock Could Double Your Money After Earnings

by Leave a Comment

Attempting to speculate around earnings season can be a tricky pastime.

While three-quarters of S&P 500 companies have topped earnings expectations this quarter, dabbling on smaller companies can create a lot of challenges for the retail investor.

Sometimes, it's best to wait and see how a company performed before diving into the company.

But how do we know which stocks have the most upside following their earnings reports?

To make that determination, I use this proprietary investing algorithm that tells me exactly when to buy, sell, or hold a stock...

stocks

The 5 Top Biotech Stocks to Buy for 2020

by 1 Comment

In 2019, some of the worst performing stocks were in the biotech sector. Since peaking in March, the Nasdaq Biotechnology Index has dipped almost 7%.

So why are we bringing you biotech stocks to buy today?

Things are about to change for the entire biotech sector...

Stocks

The 3 Best Biotech Stocks to Buy in Q4 2019

by Leave a Comment

Investors hate uncertainty. If the future of a business or industry is in question, stocks suffer.

That's certainly the case with the biotech sector right now. In 2019, biotech stocks have been pummeled. The Nasdaq Biotech Index is down almost 12% over the last six months.

What's holding back the group? Uncertainty about drug prices is a huge overhang for biotech stocks

But a lot of that uncertainty was just removed, meaning the best biotech stocks to buy in Q4 could skyrocket soon...

Marijuana Industry

Medical Marijuana Stocks Will Get a Boost from This Cancer Breakthrough

by Leave a Comment

Cannabis has already proven to be a boon for health and wellness. From easing the side effects of chemotherapy to treating epilepsy, and even being part of a calming lotion or edible, we are still just scratching the surface of what this wonder plant can do. And now we are learning that cannabis was found […]

And this is the best one to buy right now...

Stocks

Three Biotech Stocks Poised to Break Out

by 1 Comment

With recession indicators flashing, investors are flocking to 10-year bonds that have the annual upside of just 1.5%.

But there are still market-beating stocks out there – in fact, one of our picks expects 103% growth.

And that brings us to the biotech industry.

There are some big biotech stocks to own right now that could deliver double, even triple-digit upside in less than 12 months.

Read more here...

GlaxoSmithKline Is Now a Top Pharmaceutical Stock to Buy

by Leave a Comment

GlaxoSmithKline doesn't appear to be a top pharmaceutical stock to buy – at least not at first glance.

Its shares have underperformed the global pharma sector by 60% over the past decade.

But since Glaxo got a new CEO in 2017, the company has been on the path to a leaner, more focused company.

And with a high Money Morning Stock VQScore™, GSK is looking very attractive indeed.

Stocks

This Deal Could Put You Up Much More Than 149%

by Leave a Comment

It was the very first stock that I recommended on the very first day we published Private Briefing nearly eight years ago…

I've re-recommended the shares to my readers several times, and when something happened that I felt everyone should know about, we made sure to get the news out in Money Morning, too.

When I first wrote about it in 2011, shares were trading at $8.60. As of Wednesday morning, the stock was sitting near all-time highs at $171 – monumental gains of nearly 1,900%.

But I'm writing today because it's been a big winner for you, too – more than 149%.

And I don't think it's done, not by a long shot…

Let me tell you about the company - and all about this latest development...

Today's Markets
DJIA 29.57 (0.11%) 27,911.30
NASDAQ 37.86 (0.44%) 8,654.05
S&P 9.11 (0.29%) 3,141.63